You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

Details for Patent: 7,816,404

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,816,404 protect, and when does it expire?

Patent 7,816,404 protects TRIFERIC and TRIFERIC AVNU and is included in three NDAs.

This patent has twelve patent family members in eleven countries.

Summary for Patent: 7,816,404

Title:	Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
Abstract:	A highly water soluble ferric pyrophosphate citrate chelate useful for treating iron deficiency contains 2% or less phosphate by weight. These chelate compositions are easily milled and/or processed into dosage forms using conventional techniques, and are expected to exhibit advantageous biocompatibility as compared to conventional soluble ferric pyrophosphates, ferric salts, ferric polysaccharide complexes and ferrous salts.
Inventor(s):	McCall, Jr.; William S. (Raleigh, NC)
Assignee:	Rockwell Medical Technologies, Inc. (Wixom, MI)
Application Number:	12/138,018
Patent Claim Types: see list of patent claims	Composition; Process; Use; Dosage form;

Drugs Protected by US Patent 7,816,404

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate	POWDER;INTRAVENOUS	208551-001	Apr 25, 2016		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up				METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT	⤷ Sign Up
Rockwell Medical Inc	TRIFERIC	ferric pyrophosphate citrate	SOLUTION;INTRAVENOUS	206317-001	Jan 23, 2015		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up	Y			METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT	⤷ Sign Up
Rockwell Medical Inc	TRIFERIC AVNU	ferric pyrophosphate citrate	SOLUTION;INTRAVENOUS	212860-001	Mar 27, 2020		DISCN	Yes	No	⤷ Sign Up	⤷ Sign Up		Y		METHOD OF IRON ADMINISTRATION TO TREAT PATIENTS IN NEED OF IRON REPLACEMENT THERAPY	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 7,816,404

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E554754	⤷ Sign Up
Canada	2638081	⤷ Sign Up
Cyprus	1113903	⤷ Sign Up
Denmark	2016940	⤷ Sign Up
European Patent Office	2016940	⤷ Sign Up
Spain	2383713	⤷ Sign Up
Croatia	P20120416	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.